Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company that uses human genetics to discover and develop small-molecule medicines for kidney, cardiovascular and metabolic diseases. Its research platform, called Compass, combines large genetic datasets with functional biology to identify gene variants that modify disease and the drug targets they point to.

The company's lead programs include MZE829, an oral inhibitor of APOL1 being developed for APOL1-mediated kidney disease, and MZE782, an oral inhibitor of the SLC6A19 transporter being studied in phenylketonuria and chronic kidney disease. It also has earlier-stage programs and has partnered certain assets with other drug developers.

Maze Therapeutics is headquartered in South San Francisco, California, and completed its initial public offering on the Nasdaq in 2025.